Form 483

Afton Scientific, LLC Form 483, 2019-06-14

FDA issued a Form 483 to Afton Scientific, LLC on 2019-06-14 with 7 public-safe observations.

483· Form 483 issuedHuman Drugs7 observations

Afton Scientific, LLC · Charlottesville, United States · Issued June 14, 2019

Overview

  • 7 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

14 Jun 2019
21 CFR 211.113(b)

Validation lacking for sterile drug products

Cited by William J Leonard, Gayle S Lawson

14 Jun 2019
21 CFR 211.142(b)

Storage under appropriate conditions

Cited by William J Leonard, Gayle S Lawson

14 Jun 2019
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by William J Leonard, Gayle S Lawson

14 Jun 2019
21 CFR 211.192

Investigations of discrepancies, failures

Cited by William J Leonard, Gayle S Lawson

14 Jun 2019
21 CFR 211.194(a)(1)

Sample identification and other information

Cited by William J Leonard, Gayle S Lawson

Inspected site

ASAfton Scientific, LLCCharlottesville, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.142(b)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)(1)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 7 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere